Lannett Company, Inc. (LCI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lannett Company, Inc. (LCI) Healthcare & Pipeline Overview

Lannett Company, Inc. focuses on developing and distributing generic pharmaceutical products in the U.S., offering a diverse range of dosage forms and therapeutic applications. With a market capitalization of $7.38M, the company faces challenges in a competitive landscape while serving a broad customer base.

What Is the Investment Thesis for LCI?

Lannett Company, Inc. faces significant challenges despite its established presence in the generic pharmaceutical market. With a small market capitalization of $7.38M and a negative profit margin of -68.0%, the company's financial performance raises concerns. While the company offers a diverse range of generic products, it operates in a highly competitive industry with pricing pressures and regulatory hurdles. Growth catalysts include potential new product approvals and strategic partnerships. However, the company's high debt levels and negative profitability pose substantial risks. Investors should carefully consider these factors and the company's ability to improve its financial performance before making any investment decisions. The ongoing industry consolidation and pricing pressures further complicate the investment outlook for Lannett.

Based on FMP financials and quantitative analysis

LCI Key Highlights

• Market capitalization of $7.38M, indicating a small-cap company.
• Negative profit margin of -68.0%, reflecting significant challenges in profitability.
• Gross margin of 9.7%, suggesting potential issues with cost management and pricing strategies.
• Beta of 0.95, indicating the stock's volatility is slightly less than the market average.
• No dividend yield, meaning the company does not currently distribute profits to shareholders.

Who Are LCI's Competitors?

LCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LCI's Key Strengths?

• Diverse product portfolio of generic drugs
• Established manufacturing and distribution network
• Supply agreements with multiple companies
• Experience in developing and marketing generic pharmaceuticals

What Are LCI's Weaknesses?

• Low market capitalization
• Negative profit margin
• High debt levels
• Dependence on generic drug pricing

What Could Drive LCI Stock Higher?

• Potential FDA approvals for new generic drug products.
• Strategic partnerships to expand product portfolio.
• Efforts to reduce operating costs and improve efficiency.

What Are the Key Risks for LCI?

• Financial-distress signal — its Altman Z-Score of -5.80 sits in the distress zone (elevated bankruptcy risk).
• Intense competition in the generic pharmaceutical industry.
• Pricing pressures and reimbursement challenges.
• Regulatory hurdles and compliance requirements.
• High debt levels and negative profitability.

What Are the Growth Opportunities for LCI?

• New Product Development and Approvals: Lannett can drive growth by focusing on the development and approval of new generic drugs, particularly those addressing unmet medical needs or targeting niche markets. Successful product launches can expand the company's revenue base and improve profitability. The timeline for this growth opportunity depends on the regulatory approval process, which can take several years. The market size for new generic drugs is substantial, with billions of dollars in potential revenue.
• Strategic Partnerships and Acquisitions: Lannett can pursue strategic partnerships or acquisitions to expand its product portfolio, enhance its manufacturing capabilities, or enter new geographic markets. Collaborations with other pharmaceutical companies can provide access to new technologies and expertise. The timeline for this growth opportunity depends on the availability of suitable partners or acquisition targets. The potential market size for strategic partnerships and acquisitions is significant, with billions of dollars in potential value.
• Expansion into Biosimilars: The biosimilars market represents a significant growth opportunity for Lannett. Biosimilars are generic versions of biologic drugs, which are complex molecules manufactured using living organisms. As more biologic drugs lose patent protection, the market for biosimilars is expected to grow rapidly. Lannett can invest in the development and manufacturing of biosimilars to capture a share of this growing market. The timeline for this growth opportunity depends on the regulatory approval process and the availability of biosimilar candidates.
• Geographic Expansion: While Lannett primarily operates in the United States, the company can explore opportunities to expand its geographic reach into other markets. International expansion can provide access to new customers and revenue streams. The timeline for this growth opportunity depends on the regulatory requirements and market dynamics in each target country. The global pharmaceutical market is vast, with trillions of dollars in potential revenue.
• Focus on High-Value Generics: Lannett can prioritize the development and marketing of high-value generic drugs, which offer higher profit margins and less competition. These drugs may include complex formulations, controlled-release products, or drugs with limited generic competition. By focusing on high-value generics, Lannett can improve its profitability and differentiate itself from other generic manufacturers. The timeline for this growth opportunity depends on the availability of suitable generic candidates and the regulatory approval process. The market size for high-value generics is substantial, with billions of dollars in potential revenue.

What Opportunities Does LCI Have?

• New product development and approvals
• Strategic partnerships and acquisitions
• Expansion into biosimilars market
• Geographic expansion into new markets

What Threats Does LCI Face?

• Intense competition in the generic pharmaceutical industry
• Pricing pressures and reimbursement challenges
• Regulatory hurdles and compliance requirements
• Product liability and litigation risks

What Are LCI's Competitive Advantages?

• Established manufacturing capabilities
• Diverse product portfolio
• Supply and development agreements
• Distribution network

What Does LCI Do?

Lannett Company, Inc., incorporated in 1942 and headquartered in Trevose, Pennsylvania, is a pharmaceutical company specializing in the development, manufacture, packaging, marketing, and distribution of generic versions of brand-name pharmaceutical products in the United States. The company offers a wide array of dosage forms, including solid oral and extended-release, topical, liquid, nasal, and oral solutions. These products address a broad spectrum of therapeutic areas, such as analgesia, anti-psychosis, cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, migraines, respiratory ailments, allergies, coughs, colds, and urinary conditions. Lannett's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. The company distributes its products to a diverse customer base, including generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. Lannett has established supply and development agreements with companies like Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, and RivoPharm, enhancing its product pipeline and manufacturing capabilities. Despite its long history and broad product portfolio, Lannett operates in a highly competitive and regulated industry, requiring continuous innovation and adaptation to maintain its market position.

What Products and Services Does LCI Offer?

• Develops generic versions of brand-name pharmaceutical products.
• Manufactures pharmaceutical products in various dosage forms.
• Packages and markets generic drugs.
• Distributes products across the United States.
• Offers a range of therapeutic products for various medical indications.
• Engages in supply and development agreements with other companies.

How Does LCI Make Money?

• Develops and manufactures generic pharmaceutical products.
• Sells products to distributors, wholesalers, and retailers.
• Generates revenue through product sales.
• Forms partnerships for product development and supply.

What Industry Does LCI Operate In?

Lannett Company, Inc. operates within the generic pharmaceutical industry, a sector characterized by intense competition and pricing pressures. The industry is driven by the expiration of patents on brand-name drugs, leading to the introduction of lower-cost generic alternatives. Companies like Lannett face the challenge of navigating complex regulatory pathways, managing manufacturing costs, and competing with larger generic manufacturers. The market is also influenced by trends such as increasing demand for affordable healthcare and ongoing consolidation among pharmaceutical distributors and retailers.

Who Are LCI's Key Customers?

• Generic pharmaceutical distributors
• Drug wholesalers
• Chain drug retailers
• Mail-order pharmacies
• Managed care organizations

How Lannett Company, Inc. Is Valued

Lannett Company, Inc. carries a market capitalization of $7.38M, placing it in the micro-cap category. Relative to its peer group, LCI's quantitative score of 39/100 is below the peer average of 56/100.

ROE 166%Key Financial Metrics

Return on equity for Lannett Company, Inc. stands at 166.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.8%, showing how much profit it generates from its asset base. A current ratio of 2.76 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

Lannett Company, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.80 places it in the distress zone, a signal of elevated financial risk.

Net buyingInsider Activity

The most recent 12 insider filings for Lannett Company, Inc. break down as 8 sales and 4 purchases. On net that is roughly 114K shares acquired (about $52K) — insiders putting money in tends to read as conviction.

LCI Financials

LCI Latest News

LCI Analyst Consensus

LCI MoonshotScore

Common Questions About LCI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources